Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and pathological features with Alzheimer's disease (AD) including extracellular deposits containing amyloid-b (Ab) peptides. Immunotherapy targeting the Ab protein has been investigated as a potential treatment for AD. Here, we present the rationale for extending this approach to treat AMD. We tested an anti-Ab antibody administered systemically in a mouse model of AMD. Histological and functional measurements in treated animals compared to controls showed that following immunotherapy, the amounts of Ab in the retina and brain were decreased and the ERG deficits in the retina were attenuated. These data support the hypothesis that Ab is a therapeutic target for AMD.
Age-related macular degeneration
Age-related macular degeneration (AMD) is a late-onset neurodegenerative retinal disease that manifests as progressive loss of central vision due to dysfunction and death of photoreceptor and adjacent retinal pigment epithelial (RPE) cells in the macula. It is the leading cause of irreversible vision loss in people over the age of 65 (Javitt, Zhou, Maguire, Fine, & Willke, 2003) . AMD is a multifactorial disease in which the relative contributions of genetic and environmental factors remain unknown. The strongest known risk factor for AMD is advanced age, however, other identified risk factors include gender, ethnicity, smoking, hypertension, hypercholesterolemia, and diet (van Leeuwen, Klaver, Vingerling, Hofman, & de Jong, 2003) . It is now established that AMD is also influenced by genetic factors, as evidenced by identification of AMD-susceptibility genes (Evans & Bird, 1996; Heiba, Elston, Klein, & Klein, 1994; Klein, Mauldin, & Stoumbos, 1994; Klein et al., 1998; Piguet et al., 1993; Silvestri, Johnston, & Hughes, 1994) . One gene implicated is APOE, a polymorphic gene in humans encoding one of three common alleles (e2, e3 and e4) with the e4 allele associated with AMD (Baird, Guida, Chu, Vu, & Guymer, 2004 protein E (apoE) is an amphipathic glycoprotein that mediates the distribution of lipids and cholesterol among cells. A Y402H polymorphism in another gene, CFH, coding for complement factor H and factor H-like protein 1, was recently shown to be the major genetic factor contributing to AMD (Edwards et al., 2005; Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005) .
Mouse model of AMD
We developed a murine model of AMD that combines three known risk factors for AMD: advanced age, apoE isoform expression and exposure to a high-fat, cholesterol-enriched (HF-C) diet (Malek et al., 2005) . Specifically, mice carrying a targeted knock-in of the human APOE e4 (APOE4) gene, aged over 1 year and fed a HF-C diet for 8 weeks develop pathological features similar to the morphologic hallmarks observed in both dry and wet human AMD. Importantly, these changes require the presence of all three risk factors. These changes were not detected in any of the control, human APOE3 expressing mice regardless of diet consumed, nor were there any pathologies detected in young APOE4 animals. This animal model of AMD with spontaneously-occurring CNV is the first to incorporate physiologically-relevant risk factors of human disease and therefore can be used to rationally identify and test therapeutic targets for intervention. To date, the results of our studies using this model suggest that lipid transport dysregulation and amyloid deposition contribute to the pathogenesis of the observed retinal changes (Malek et al., 2005) .
Alzheimer's disease, amyloid and Ab
Like AMD, AD is a multifactorial disease affected by age, environmental factors and genetics. In AD the major genetic risk factor is APOE. The common APOE gene polymorphisms are linked to 90% of cases <65 years of age and 60% of AD cases >65 years. Whereas the function of apoE in the central nervous system remains unclear, apoE functions in the periphery by maintaining cholesterol and triglyceride homeostases (Mahley, 1988) . The pathological hallmarks of AD include the presence of senile plaques, neurofibrillary tangles, neuronal cell loss, reactive gliosis and, in some cases, cerebrovascular amyloid deposits (reviewed by Blennow, de Leon, & Zetterberg, 2006) . Senile plaques are generated by deposition and accumulation of the amyloid-b (Ab) peptides. Cholesterol has been linked to amyloidogenesis, and there is increasing evidence of the importance of cholesterol as a risk factor for AD through both intracellular and extracellular mechanisms (Canevari & Clark, 2007) .
Ab peptides are derived from amyloid precursor protein (APP) through sequential, proteolytic cleavage at the Nterminus by b-secretase and at the C-terminus by c-secretase. The c-secretase is unique among proteases in that it cleaves APP in the transmembrane region, resulting in a peptide of 40 or 42 amino acids in length (Ab1-40 or 1-42). After Ab1-40 or 1-42 peptides are generated, its N-terminus can be further modified or cleaved, yielding N-terminal truncated peptides Abx-40 or Abx-42 (Arai, Akiyama, Ikeda, Kondo, & Mori, 1999) . Mutations of APP and presenilins (PS1 and PS2, integral components of the c-secretase protease complex) have been identified in familial forms of AD. APP-overexpressing and APP/ PS1 double transgenic mice exhibit brain deposits of amyloid (plaques) and accompanying memory impairment, underscoring the notion that accelerated Ab peptide production is sufficient to lead to AD.
Ab immunotherapies
Immunotherapies targeting the Ab peptide, using vaccines or antibodies, have been applied to several different strains of APP-based mouse models of AD to reduce amyloid plaques and improve cognitive performance (Hardy & Selkoe, 2002) . Although promising, phase 2 clinical trials of the first generation Ab vaccine AN-1792 (Elan/Wyeth) were halted after a significant number of patients (6%) developed autoimmune meningoencephalitis characterized by perivascular infiltration, due primarily to brain infiltration of autoreactive T lymphocytes in response to active immunization (Ferrer, Boada Rovira, Sanchez Guerra, Rey, & Costa-Jussa, 2004; Nicoll et al., 2003; Orgogozo et al., 2003) . Importantly, unlike typical AD patients, the AN-1792 treated AD patients undergoing autopsy were found to have extremely low amyloid burdens in their cerebral cortex, suggesting the tantalizing possibility that the vaccine was, in fact, effective in removing the amyloid plaques (Masliah et al., 2005; Nicoll et al., 2003) .
To reduce the risk of uncontrolled CNS inflammation associated with active vaccines, passive immunization using a monoclonal antibody targeting the N-terminus (Bapineuzumab, Elan/Wyeth) or the middle portion (LY2062430, Eli Lilly) of the Ab peptide are now under investigation in phase 2 clinical studies (Melnikova, 2007) . However, as mentioned above, the N-terminal portion of Ab peptides are often truncated, rendering the monoclonal antibodies targeting the N-terminus ineffective for these truncated Ab peptides in the AD brain. On the other hand, antibodies recognizing the middle portion of the Ab peptides can also bind the full length APP protein normally found on the cell surface in the CNS, creating a potential safety risk for neurons and other healthy APP expressing cells in patients.
Therefore, we turned our attention to the novel therapeutic approach of targeting Ab peptides at the C-terminus. These C-terminal epitopes are normally buried in the lipid bilayer and are exposed, predominantly, in the pathological state. Two different C-terminal x-40 specific monoclonal antibodies, 2286 and 2H6, were identified and tested in Tg2576 APP-overexpressing mouse model (Wilcock et al., 2004) . Both antibodies, given either intracranially or peripherally, were effective in reducing brain levels of amyloid plaques and improving cognitive behaviors. The peripheral administration of these C-terminal x-40 specific antibodies was also accompanied by a 10-to 100-fold increase in circulating Ab peptide levels, supporting the notion that Ab antibodies in the periphery create a sink, pulling soluble brain Ab into the blood for clearance. Since both 2286 and 2H6 antibodies have native mouse immunoglobulin constant regions that can mediate immune effector functions, such as binding to Fcc receptors, complement fixation and antibody-dependent cell-mediated cytotoxicity (ADCC), we sought to further reduce the potential safety risk of C-terminal specific Ab antibodies. In previous studies, deglycosylated 2H6 (i.e. 2H6-D) did not bind any Fcc-I receptors, complement or mediate any detectable ADCC. The administration of 2H6-D in Tg2576 mice, while still effective in ameliorating the AD pathology and behavioral deficits, was associated with significantly lower levels of microhemorrhages and inflammation in the brain than the parent antibody, 2H6 (Carty et al., 2006; Wilcock et al., 2006) .
Rationale for Ab immunotherapy in AMD
As mentioned above, AD and AMD share several striking pathological features in common. First and foremost, the risk of AD and AMD both increase dramatically with advanced age. Furthermore, they are both associated with pathological, extracellular deposits consisting of Ab peptides, apoE protein, complement and other components.
In human AMD, Ab deposition was associated with drusen from AMD eyes, but not with drusen in normal eyes (Dentchev, Milam, Lee, Trojanowski, & Dunaief, 2003) , where it accumulates and co-localizes with activated complement components within drusen (Anderson et al., 2004; Johnson et al., 2002) . Likewise, we detected Ab peptide in aged APOE4 mice exposed to a HF-C diet (APOE4-HFC) but not in control animals (Malek et al., 2005) . In addition, human CNV membranes and neovascular (NV) tissue from APOE4-HFC mice display perivascular Ab immunoreactivity, whereas Ab immunoreactivity was also detected in subRPE deposits in our AMD model (Malek et al., 2005) . A pathogenic role for amyloid in AMD was proposed by Yoshida et al. in studies showing that Ab increases VEGF mRNA and protein levels in primary cultures of human RPE cells, (Yoshida et al., 2005) , and evidence of amyloid toxicity was shown by Luibl et al. who detected nonfibrillar oligomeric Ab in drusen from AMD eyes (Luibl et al., 2006) .
Based on (1) the detection of amyloid in both our animal model and in AMD patients, (2) the findings that APOE genotype regulates Ab cytotoxicity and (3) the considerable overlap between the pathologies of AMD and AD, we tested the hypothesis that Ab is a toxic, pathogenic component of basal deposits by using an anti-Ab antibody to deplete Ab in a mouse model of AMD to determine if this could ameliorate the disease.
6. Pilot study of anti-Ab in AMD mouse 6.1. Methods
Animals
Mice were maintained and bred in accordance with the Institutional Animal Care and Use Committee at Duke University and the Association for Research in Vision and Ophthalmology statement for the use of animals in ophthalmic and vision research. APOE4 targeted replacement (TR) mice expressing the human apoE4 isoform under control of the endogenous mouse apoE regulatory sequences, were generated as previously described (Sullivan et al., 1997) .
Experimental protocol, diet and antibody administration paradigm
A small cohort of aged male (n = 19; 72-120 weeks) C57Bl/6 APOE4 TR mice housed conventionally, under ambient conditions were switched from normal mouse chow (ND, Isopurina #5001; Prolab, Dewitt, NY) to a high fat diet rich in cholesterol (HF-C, #T.D. 88051; Harlan Teklad, Indianapolis, IN) for 8 weeks immediately prior to analysis as previously described (Malek et al., 2005) . Age-matched normal control APOE4 TR littermates (''APOE4-ND'', n = 3) were fed ND and water ad libitum. The HF-C fed APOE4 mice (APOE4-HFC) were assigned to one of three groups based on antibody treatment as follows:
(1) Uninjected controls (n = 3), ''APOE4-HFC-uninj'', received no injections. Antibodies, antibody doses and injection paradigm used were based on parameters established by previously in AD mouse models . At the end of the diet/ injections exposure, mice were euthanized with an overdose of avertin and flushed with a 20 ml bolus of saline.
Electroretinogram (ERG) recordings
The ERG recordings were obtained from animals, dark adapted for at least 12 h prior to recording. Each animal was anesthetized with a ketamine/xylazine cocktail, pupils were dilated and after the animal stabilized on a 37°C warming pad, ERG tracings were recorded using a silver fiber test electrode placed in contact with the eye along with a drop of 2.5% hydroxypropyl methylcellulose. Each mouse was exposed to flashes of light (max intensity of 1000 cd-s/m 2 attenuate in 1 log steps, starting from 0.0005). The a-wave amplitude was measured from baseline to the a-wave trough, and the b-wave amplitude was measured from the a-wave trough to the b-wave peak.
Histology and immunohistochemistry
Eyes were immersion fixed in 4% paraformaldehyde for 2 h and transferred to 2% paraformaldehyde and stored at 4°C until processing for light microscopy. The anterior segment was removed and posterior segment was cryo-protected with serial sucrose (10%, 20% and 30%) solution. Frozen sections were cut on a cryostat at 10 lm. Sections were treated with 3% H 2 O 2 for 30 min, preincubated with 10% BSA, and incubated overnight with biotinylated monoclonal mouse anti-Ab antibody (1:100; clone 4G8, Signet). The signal was then amplified using a TSA biotin kit (Perkin-Elmer), following the manufacturer's instructions. Sections were then incubated with streptavidin-conjugated Alexa Fluore 594, to visualize the signal. For quantification, 3-4 images were randomly taken for each of five antibody-treated and five saline-treated animals. Ab-positive puncta in basal deposits and BM were Fig. 1 . b-wave in aged APOE4 mice fed a normal or HF-C diet and in aged APOE4-HFC's injected with anti-Ab antibody (HFC-aAb) or with saline vehicle control (HFC-con). V-log I intensity response curves of the b-waves. Baseline ERGs (n = 12-14) obtained from APOE4-ND controls (black) and APOE4-HFC controls (red). E4-HFC-con vehicle injected (green), E4-HFC-aAb (blue). Data are plotted with SE bars. The b-wave in the antibody-treated animals is preserved compared to the saline-treated group (p < 0.2, equal variance two-tailed t-test). counted, and the length of BM was also measured. Results are presented as linear density along BM.
The brain was immersion fixed in 10% buffered formalin (4% formaldehyde, pH 7.4) for 18 h at 4°C, prior to being transferred to 1· PBS, pH 7.4, 4°C. The brain was then sagitally sectioned on an Oxford vibratome at 30 lm then reacted as free-floating sections. Ab immunohistochemistry (IHC) was performed with the biotin-avidin-peroxidase method, using diaminobenzidine (DAB) as a chromogen (Vector Laboratories, CA). All tissue sections including controls are run simultaneously to avoid inter-run variability. No antibody was used for visualizing background reactivity for negative control for each animal. IHC tissue is pretreated in 10% methanol and 2% peroxide in PBS and then 88% formic acid for 1 min. After blocking in serum, the tissue is incubated with a biotinlyated mouse anti-human Ab monoclonal (1:2000) (4G8, Senetek, Napa, CA) at room temperature, 2 h. The tissue is then incubated with an avidin-biotin conjugate ABC reagent, as manufacture instructions (Vector Laboratories, CA). DAB (1.39 mM) in 1· PBS, 0.01% peroxide is used as the chromogen for visualization of staining. No secondary staining was used. Stained slides were examined under light microscopy (Nikon optiphot-2). In order to eliminate any bias in analyzing the tissue, several pictures from each section were digitally captured by a cooled CCD camera Penguin 660cl (Pixera). 
Results

ERG recordings
We have previously shown that aged APOE4 animals following exposure to the HF-C diet for 8 weeks (APOE4-HFCs) develop AMD-associated ocular pathologies (Malek et al., 2005) , and that in these animals there was statistically significant reduction in the a-and b-wave amplitudes compared to age-matched, histologically normal control APOE4 mice maintained on the normal rodent chow diet, APOE4-ND (Malek, Jamison, Mace, Sullivan, & Bowes Rickman, 2007 ). In the current pilot cohort of aged APOE4-HFC mice that were either uninjected or received 8 weekly IP injections of the saline-control a similar decrease in the b-wave amplitudes was observed compared to the normal APOE4-ND (Fig. 1) . In contrast, there was a preservation of the b-wave amplitude in the APOE4-HFC mice that received 8 weekly IP injections of the anti-Ab antibody (blue trace, Fig. 1) . A similar trend was observed in the a-wave amplitudes though it was not as robust (data not shown).
Amyloid immunohistochemistry
Consistent with the improvement of ERG, total Ab immunostaining in the retina of the E4-HFC mice was reduced after 8 weeks immunotherapy with antibody 2H6-D as compared to the control vehicle group, as illustrated in Fig. 2 . On average, the control saline-treated group had 116 puncta per 1 mm of BM, whereas anti-Ab antibody-treated group had 41 ( Fig. 2 ; p = 0.048, onetailed t-test). Similarly, the diffuse amyloid plaques revealed by the total Ab immunostaining in the cerebral cortex of the E4-HFC mice were also greatly reduced after 8 weeks immunotherapy with antibody 2H6-D relative to the control vehicle group (Fig. 3) . Vascular amyloid in the brain was more prevalent in untreated E4-HFC animals (not shown).
These preliminary findings demonstrate (1) preservation of retinal function as demonstrated by ERGs of mice injected with the anti-Ab antibody, 2H6-D and 2) reduction of amyloid deposition when treated with anti-Ab antibody in mouse retina and cortex as compared to the untreated AMD mouse group.
Summary and future directions
Despite the shared similarities between AD and AMD, AMD has thus far not been classified as an amyloid disease. Among the principal differences is the fact that classical amyloid diseases typically exhibit large amounts of amyloid fibrils (Soto, 2003) . For example, in the case of AD, the characteristic plaques consist primarily of fibrillar Alzheimer Ab peptide. Amyloid fibrils display characteristic tinctorial properties, such as thioflavin T and congo red staining (Krebs, Bromley, & Donald, 2005; LeVine, 1999; Puchtler & Sweat, 1965) . Though drusen do stain with thioflavin T and congo red, the characteristic birefringence often seen in congo red-stained amyloid fibrils is not present (Anderson et al., 2004; Mullins, Russell, Anderson, & Hageman, 2000) .
Even though AMD is not widely considered as a prototypical amyloid disease, previous studies from several laboratories, including ours, have localized Ab peptidederived amyloid within subRPE deposits and CNV in human AMD eyes and our murine model implicate Ab amyloid in AMD pathogenesis. This is further supported by our pilot immunotherapy study targeting Ab described above.
These findings, though preliminary, contribute to understanding underlying mechanisms of pathology specifically related to the role of amyloid in sub-RPE deposit formation and retinal changes in AMD. These experiments support the feasibility of immunotherapeutic strategies targeting amyloid as treatments for AMD. Finally, our pilot data also suggest the exciting prospect that, in the aging population, two of the most common neurodegenerative diseases, AD and AMD, could simultaneously be treated or prevented with a single therapeutic agent, such as the anti-Ab antibody.
